{
    "clinical_study": {
        "@rank": "99034", 
        "acronym": "Adherence", 
        "arm_group": {
            "arm_group_label": "Rheumatoid,-Psoriatic Arthritis, Bechterew", 
            "description": "Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, unsatisfactory disease modifying antirheumatic drugs response and or biological disease modifying antirheumatic drugs"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether or not adalimumab (Humira\u00ae) can influence\n      pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA)\n      and ankylosing spondylitis (AS) with or without comorbidities, which do not constitute a\n      contraindication for adalimumab as stated in the released summary of product\n      characteristics. Therefore it shall be evaluated if pain medication which is used in these\n      participants is changed, reduced or stopped due to adalimumab treatment."
        }, 
        "brief_title": "Assessment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients`Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Rheumatoid Arthritis", 
            "Ankylosing Spondylitis", 
            "Psoriatic Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Arthritis, Rheumatoid", 
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a non-interventional, observational study in which Humira (adalimumab) is prescribed\n      in the usual manner in accordance with the terms of the local marketing authorization with\n      regards to dose, population and indication. The assignment of the patient to a\n      Humira-containing regimen has to be decided in advance and has to be current practice. The\n      prescription of Humira is clearly separated from the decision to include the participant in\n      this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged >=18 years with RA, PsA, AS\n\n          -  Patients must fulfill international and national guidelines for the use of a BDMARD\n             in RA,\n\n          -  PsA, AS (Chest X-ray and IGRA interferon gamma release assay or PPD-skin test\n             negative for tuberculosis). In addition one of the following criteria must be\n             fulfilled:\n\n               -  unsatisfactory DMARD response defined as failure to treatment with at least two\n                  DMARDs including Methotrexate in patients with RA or PsA\n\n               -  unsatisfactory NSAID response in patients with AS\n\n               -  unsatisfactory response to prior BDMARDs in patients with RA or PsA or AS.\n\n        Exclusion Criteria:\n\n          -  Patients who are not covered in the latest version of the Humira syringe\u00ae SPC and\n             Humira Pen\u00ae SPC;\n\n          -  Patients participating in another study program or clinical trial.\n\n          -  Patients who have been treated with Humira\u00ae before"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "primary care clinic and medical practice specialized in rheumatology"
            }
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768858", 
            "org_study_id": "P13-562"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adalimumab", 
                "Antirheumatic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ankylosing", 
            "Rheumatoid", 
            "Antibodies", 
            "Arthritis", 
            "Adherence", 
            "Antirheumatic Agents", 
            "Psoriatic", 
            "Spondylitis", 
            "Monoclonals"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "link": {
            "url": "http://rxabbbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "A-8020"
                    }, 
                    "name": "Site Reference ID/Investigator# 69653"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Klagenfurt", 
                        "country": "Austria", 
                        "zip": "A-9020"
                    }, 
                    "name": "Site Reference ID/Investigator# 69655"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4030"
                    }, 
                    "name": "Site Reference ID/Investigator# 69650"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "A-4020"
                    }, 
                    "name": "Site Reference ID/Investigator# 69652"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neudorf", 
                        "country": "Austria", 
                        "zip": "A-2351"
                    }, 
                    "name": "Site Reference ID/Investigator# 69645"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spitz", 
                        "country": "Austria", 
                        "zip": "3620"
                    }, 
                    "name": "Site Reference ID/Investigator# 69649"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "1030"
                    }, 
                    "name": "Site Reference ID/Investigator# 69646"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voecklabruck", 
                        "country": "Austria", 
                        "zip": "A-4840"
                    }, 
                    "name": "Site Reference ID/Investigator# 69658"
                }
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patient`s Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice", 
        "overall_official": {
            "affiliation": "AbbVie Austria", 
            "last_name": "Astrid  Dworan-Timler, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Austria: Federal Office for Safety in Health Care", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The BMQ-Specific comprises two 5-item factors assessing beliefs about the necessity of prescribed medication (Specific-Necessity) and concerns about prescribed medication based on beliefs about the danger of dependence and long-term toxicity and the disruptive effects of medication (Specific-Concern) The BMQ-General comprises two 4-item factors assessing beliefs that medicines are harmful, addictive, poisons which should not be taken continuously(General-Harm) and that medicines are over used by doctors (General-Overcure). The total score, the sum of all the points from the Specific AND General questions range from 17 (lowest score) to 85 (highest score). Patients who have positive beliefs about medicine have a score < 47 and patients who have negative beliefs have a score > 47.", 
            "measure": "Changes in the Beliefs about Medicines Questionnaire (BMQ) for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis patients (AS)", 
            "safety_issue": "No", 
            "time_frame": "from Day 0 to month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768858"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The 11-item Treatment Satisfaction Questionnaire for Medication (TSQM) Version II is an instrument to assess patients' satisfaction with medication, providing scores on four scales \u00e2\u20ac\" side effects, effectiveness, convenience and global satisfaction. The 11 questions can be answered either with yes/no or by means of a five or seven stage scale (e.g. ranging from very unsatisfied to satisfied). SCALE SCORING ALGORITHM: TSQM Scale scores range from 0 to 100 and no computed score should be lower or higher than these limits. Higher scores represent higher satisfaction.", 
                "measure": "Changes in Treatment Satisfaction Questionnaire for Medication for rheumatoid arthritis and if reasonable in patients with psoriatic arthritis over Time", 
                "safety_issue": "No", 
                "time_frame": "from month 3 to month 12"
            }, 
            {
                "description": "The Rheumatoid Arthritis Disease Activity Index  is a questionnaire which measures disease activity", 
                "measure": "Changes in Rheumatoid Arthritis Disease Activity Index in patients with rheumatoid arthritis and if reasonable in patients with psoriasis arthritis", 
                "safety_issue": "No", 
                "time_frame": "from day 0 to month 12"
            }, 
            {
                "description": "The Bath Ankylosing Spondylitis Disease Activity Index  consists of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (=enthesitis), duration of morning stiffness, severity of morning stiffness", 
                "measure": "Changes in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis", 
                "safety_issue": "No", 
                "time_frame": "from Day 0 to month 12"
            }, 
            {
                "description": "The ESR is a practicable and sensitive but not specific parameter for measuring disease progression. By means of the ESR it can be generally distinguished between an active and non active rheumatic disease.", 
                "measure": "Changes in Erythrocyte Sedimentation Rate (ESR) over time", 
                "safety_issue": "No", 
                "time_frame": "from Day 0 to month 12"
            }, 
            {
                "description": "The CRP is an acute phase reactant plasma protein, normally produced by the liver, which is commonly used as an indirect measure of the extent and activity of an inflammation.", 
                "measure": "Changes in C-reactive protein (CRP) over time", 
                "safety_issue": "No", 
                "time_frame": "from Day 0 to month 12"
            }, 
            {
                "description": "The MMAS is a 4-item Self-Report Measure of Medication-Taking Behavior. It measures both intentional and nonintentional non-adherence (based on forgetting, carelessness, stopping medication when feeling better, or stopping medication when feeling worse). The 4-item MMAS-4-item consists of 4 questions which can be answered with yes (=0 point) and no (=1point). The MMAS score is the sum of all four question and range from 0 (=non-adherent) to 4 (=adherent).", 
                "measure": "Changes in Morisky Medication Adherence Scale (MMAS) for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients.", 
                "safety_issue": "No", 
                "time_frame": "from month 3 to month 12"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Raffeiner GmbH", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "BIOCONSULT GmbH", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}